author-photo

Robert H. Jones

Cardiff University

11

Papers

158

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling

2021 Frontiers in Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.

2020 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (30)
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation.

2009 Oncogene
Show All
- Source
- Cite
- Save
Citations (38)